OPKO Health, Inc. (0KCS.L)
USD 1.46
(2.83%)
USD 1.46
(2.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -157.02 Million USD | 35.8% |
| 2022 | -246.2 Million USD | -416.14% |
| 2021 | -47.7 Million USD | -182.67% |
| 2020 | 57.7 Million USD | 129.35% |
| 2019 | -196.6 Million USD | -14.84% |
| 2018 | -171.2 Million USD | 38.07% |
| 2017 | -276.44 Million USD | -277.14% |
| 2016 | -73.3 Million USD | 25.58% |
| 2015 | -98.5 Million USD | 32.44% |
| 2014 | -145.8 Million USD | -83.09% |
| 2013 | -79.63 Million USD | -113.67% |
| 2012 | -37.26 Million USD | -60.72% |
| 2011 | -23.18 Million USD | -108.23% |
| 2010 | -11.13 Million USD | 60.26% |
| 2009 | -28.02 Million USD | 27.34% |
| 2008 | -38.56 Million USD | 85.6% |
| 2007 | -267.85 Million USD | -23880.21% |
| 2006 | -1.11 Million USD | 22.32% |
| 2005 | -1.43 Million USD | 29.89% |
| 2004 | -2.05 Million USD | 45.04% |
| 2003 | -3.73 Million USD | 58.63% |
| 2002 | -9.02 Million USD | 14.24% |
| 2001 | -10.51 Million USD | -22.25% |
| 2000 | -8.6 Million USD | -107.28% |
| 1999 | -4.15 Million USD | -38.37% |
| 1998 | -3 Million USD | 9.09% |
| 1997 | -3.3 Million USD | -10.0% |
| 1996 | -3 Million USD | -36.36% |
| 1995 | -2.2 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -71.47 Million USD | -3.43% |
| 2024 Q2 | -61.67 Million USD | 13.71% |
| 2023 Q1 | -30.5 Million USD | 48.39% |
| 2023 Q2 | 7.02 Million USD | 123.03% |
| 2023 Q3 | -64.4 Million USD | -1016.73% |
| 2023 FY | -158.05 Million USD | 35.8% |
| 2023 Q4 | -69.1 Million USD | -7.3% |
| 2022 Q2 | -10.73 Million USD | 85.19% |
| 2022 Q1 | -72.53 Million USD | -14.94% |
| 2022 FY | -246.2 Million USD | -416.14% |
| 2022 Q3 | -88.57 Million USD | -724.79% |
| 2022 Q4 | -59.1 Million USD | 33.28% |
| 2021 FY | -47.7 Million USD | -182.67% |
| 2021 Q1 | 38.43 Million USD | -22.03% |
| 2021 Q4 | -63.1 Million USD | -266.82% |
| 2021 Q3 | 37.82 Million USD | 578.98% |
| 2021 Q2 | 5.57 Million USD | -85.51% |
| 2020 Q4 | 49.3 Million USD | 124.71% |
| 2020 Q1 | -40.76 Million USD | 63.77% |
| 2020 Q3 | 21.93 Million USD | -19.28% |
| 2020 FY | 57.7 Million USD | 129.35% |
| 2020 Q2 | 27.17 Million USD | 166.68% |
| 2019 Q4 | -112.5 Million USD | -188.38% |
| 2019 Q1 | -75.3 Million USD | 16.33% |
| 2019 Q2 | -47.26 Million USD | 37.24% |
| 2019 Q3 | -39.01 Million USD | 17.45% |
| 2019 FY | -196.6 Million USD | -14.84% |
| 2018 Q3 | -33.46 Million USD | -555.13% |
| 2018 Q4 | -90 Million USD | -168.95% |
| 2018 Q1 | -42.6 Million USD | 72.27% |
| 2018 FY | -171.2 Million USD | 38.07% |
| 2018 Q2 | -5.1 Million USD | 88.01% |
| 2017 Q4 | -153.6 Million USD | -163.51% |
| 2017 Q3 | -58.29 Million USD | -120.44% |
| 2017 Q1 | -41.7 Million USD | 17.25% |
| 2017 Q2 | -26.44 Million USD | 36.6% |
| 2017 FY | -276.44 Million USD | -277.14% |
| 2016 FY | -73.3 Million USD | 25.58% |
| 2016 Q4 | -50.4 Million USD | -112.66% |
| 2016 Q3 | -23.7 Million USD | -183.85% |
| 2016 Q2 | 28.26 Million USD | 202.72% |
| 2016 Q1 | -27.51 Million USD | -248.33% |
| 2015 Q4 | -7.9 Million USD | 3.93% |
| 2015 Q1 | -56.91 Million USD | -75.12% |
| 2015 Q2 | -25.4 Million USD | 55.36% |
| 2015 Q3 | -8.22 Million USD | 67.64% |
| 2015 FY | -98.5 Million USD | 32.44% |
| 2014 Q4 | -32.5 Million USD | 32.57% |
| 2014 Q2 | -34.88 Million USD | -15.22% |
| 2014 FY | -145.8 Million USD | -83.09% |
| 2014 Q1 | -30.27 Million USD | 15.58% |
| 2014 Q3 | -48.2 Million USD | -38.17% |
| 2013 Q2 | -17.98 Million USD | -165.51% |
| 2013 FY | -79.63 Million USD | -113.67% |
| 2013 Q4 | -35.86 Million USD | -88.67% |
| 2013 Q3 | -19.01 Million USD | -5.71% |
| 2013 Q1 | -6.77 Million USD | 30.26% |
| 2012 Q3 | -9.36 Million USD | -0.3% |
| 2012 Q2 | -9.34 Million USD | -5.58% |
| 2012 Q4 | -9.71 Million USD | -3.66% |
| 2012 Q1 | -8.84 Million USD | -4.39% |
| 2012 FY | -37.26 Million USD | -60.72% |
| 2011 Q3 | -5.8 Million USD | -12.44% |
| 2011 FY | -23.18 Million USD | -108.23% |
| 2011 Q4 | -8.47 Million USD | -46.02% |
| 2011 Q2 | -5.16 Million USD | -1.49% |
| 2011 Q1 | -5.08 Million USD | -470.18% |
| 2010 FY | -11.13 Million USD | 60.26% |
| 2010 Q2 | -5.52 Million USD | -35.93% |
| 2010 Q4 | -892 Thousand USD | 86.77% |
| 2010 Q1 | -4.06 Million USD | 51.23% |
| 2010 Q3 | -6.74 Million USD | -22.02% |
| 2009 Q2 | -5.24 Million USD | 38.86% |
| 2009 Q1 | -8.58 Million USD | 7.53% |
| 2009 FY | -28.02 Million USD | 27.34% |
| 2009 Q4 | -8.33 Million USD | -42.42% |
| 2009 Q3 | -5.85 Million USD | -11.57% |
| 2008 Q4 | -9.28 Million USD | -16.29% |
| 2008 FY | -38.56 Million USD | 85.6% |
| 2008 Q1 | -10.63 Million USD | -18.97% |
| 2008 Q2 | -10.66 Million USD | -0.35% |
| 2008 Q3 | -7.98 Million USD | 25.19% |
| 2007 Q1 | -12 Thousand USD | 97.48% |
| 2007 Q4 | -8.93 Million USD | -603.78% |
| 2007 Q3 | 1.77 Million USD | 116.47% |
| 2007 Q2 | -10.77 Million USD | -89675.0% |
| 2007 FY | -267.85 Million USD | -23880.21% |
| 2006 Q2 | -170 Thousand USD | 9.57% |
| 2006 Q3 | -280 Thousand USD | -64.71% |
| 2006 Q4 | -477 Thousand USD | -70.36% |
| 2006 FY | -1.11 Million USD | 22.32% |
| 2006 Q1 | -188 Thousand USD | 56.28% |
| 2005 Q2 | -484 Thousand USD | -46.22% |
| 2005 FY | -1.43 Million USD | 29.89% |
| 2005 Q4 | -430 Thousand USD | -121.65% |
| 2005 Q3 | -194 Thousand USD | 59.92% |
| 2005 Q1 | -331 Thousand USD | -2.48% |
| 2004 Q4 | -323 Thousand USD | 19.05% |
| 2004 FY | -2.05 Million USD | 45.04% |
| 2004 Q2 | -560 Thousand USD | 27.18% |
| 2004 Q3 | -399 Thousand USD | 28.75% |
| 2004 Q1 | -769 Thousand USD | -205.49% |
| 2003 Q2 | -1.84 Million USD | -73.63% |
| 2003 Q1 | -1.06 Million USD | 50.56% |
| 2003 Q3 | -1.55 Million USD | 15.67% |
| 2003 FY | -3.73 Million USD | 58.63% |
| 2003 Q4 | 729 Thousand USD | 146.88% |
| 2002 Q1 | -1.96 Million USD | 16.64% |
| 2002 Q2 | -2.06 Million USD | -4.72% |
| 2002 FY | -9.02 Million USD | 14.24% |
| 2002 Q3 | -2.84 Million USD | -37.78% |
| 2002 Q4 | -2.14 Million USD | 24.39% |
| 2001 Q3 | -3.04 Million USD | 8.27% |
| 2001 Q4 | -2.36 Million USD | 22.33% |
| 2001 FY | -10.51 Million USD | -22.25% |
| 2001 Q1 | -1.79 Million USD | 4.87% |
| 2001 Q2 | -3.31 Million USD | -84.27% |
| 2000 FY | -8.6 Million USD | -107.28% |
| 2000 Q1 | -2.49 Million USD | -117.03% |
| 2000 Q4 | -1.89 Million USD | 23.93% |
| 2000 Q2 | -1.72 Million USD | 30.78% |
| 2000 Q3 | -2.48 Million USD | -43.78% |
| 1999 Q3 | -1 Million USD | -25.0% |
| 1999 FY | -4.15 Million USD | -38.37% |
| 1999 Q4 | -1.15 Million USD | -15.1% |
| 1999 Q2 | -800 Thousand USD | 33.33% |
| 1999 Q1 | -1.2 Million USD | -33.33% |
| 1998 Q4 | -900 Thousand USD | 18.18% |
| 1998 FY | -3 Million USD | 9.09% |
| 1998 Q1 | -700 Thousand USD | 12.5% |
| 1998 Q2 | -300 Thousand USD | 57.14% |
| 1998 Q3 | -1.1 Million USD | -266.67% |
| 1997 FY | -3.3 Million USD | -10.0% |
| 1997 Q1 | -600 Thousand USD | 25.0% |
| 1997 Q2 | -700 Thousand USD | -16.67% |
| 1997 Q3 | -900 Thousand USD | -28.57% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1996 FY | -3 Million USD | -36.36% |
| 1996 Q1 | -600 Thousand USD | 0.0% |
| 1996 Q2 | -600 Thousand USD | 0.0% |
| 1996 Q3 | -800 Thousand USD | -33.33% |
| 1996 Q4 | -800 Thousand USD | 0.0% |
| 1995 FY | -2.2 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 59.891% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -225.77% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -41.953% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 107.942% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 41.372% |
| Homology Medicines, Inc. | -48.25 Million USD | -225.398% |
| Imunon, Inc. | -21.03 Million USD | -646.637% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 65.906% |
| uniQure N.V. | -282.87 Million USD | 44.49% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -61.284% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -113.651% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 43.11% |
| bluebird bio, Inc. | -244.26 Million USD | 35.716% |
| Blueprint Medicines Corporation | -486.27 Million USD | 67.71% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -29.241% |
| Adicet Bio, Inc. | -152.03 Million USD | -3.277% |
| Dynavax Technologies Corporation | -37.02 Million USD | -324.06% |
| Geron Corporation | -193.94 Million USD | 19.038% |
| Illumina, Inc. | -1.06 Billion USD | 85.311% |
| Myriad Genetics, Inc. | -123.7 Million USD | -26.937% |
| Verastem, Inc. | -92.08 Million USD | -70.519% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.645% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.289% |
| Biogen Inc. | 1.29 Billion USD | 112.108% |
| Nektar Therapeutics | -137.42 Million USD | -14.259% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -55.733% |
| Perrigo Company plc | 151.9 Million USD | 203.371% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -251.537% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 162.583% |
| Editas Medicine, Inc. | -169.18 Million USD | 7.188% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -0.937% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 114.442% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2880.091% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.884% |
| Waters Corporation | 817.67 Million USD | 119.203% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -248.337% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 180.755% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 42.694% |
| Evolus, Inc. | -49.23 Million USD | -218.934% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.88% |
| FibroGen, Inc. | -281.81 Million USD | 44.282% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 111.631% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 44.353% |
| Exelixis, Inc. | 170.88 Million USD | 191.887% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -181.622% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 69.528% |
| Zoetis Inc. | 3.06 Billion USD | 105.116% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 32.267% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -301.045% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 55.61% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 246.363% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 146.515% |
| Insmed Incorporated | -709.62 Million USD | 77.873% |
| TG Therapeutics, Inc. | 20.63 Million USD | 861.019% |
| Incyte Corporation | 620.52 Million USD | 125.305% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 78.384% |